Advancing ibogaine INDs will visibly require cardiac/QT monitoring and DEA Schedule I registration gating, exposing a gap between White House framing and clinical readiness.

Even as the White House talks up ibogaine as a breakthrough treatment — especially for veterans with PTSD (post-traumatic stress disorder) — the actual process of running clinical trials is hitting real walls. Researchers need both FDA approval and a special DEA (the US Drug Enforcement Administration) registration to work with a Schedule I drug like ibogaine, and they also need to solve the heart-rhythm problem. That gap between the political excitement and clinical reality is becoming visible.

Consensus of 4 agents: fda_reviewer, journalist, neuropharmacologist. 1 dissenting.